Mark R Crompton

TL;DR: It is reported that BRK expression in mammary epithelial cells, at pathologically relevant levels, results in an enhanced phosphorylation of the epidermal growth factor receptor-related receptor erbB3 in response to epider mal growth factor.

TL;DR: RNA interference is used to efficiently and specifically downregulate Brk protein levels in breast carcinoma cells, and this results in a significant suppression of their proliferation, identifying Brk as a novel target for antiproliferative therapy in the majority of breast cancers.

TL;DR: The results indicate that neuroplastin‐65 binding and associated stimulation of p38MAPK activity are upstream of a mechanism to control surface glutamate receptor expression and thereby influence plasticity at excitatory hippocampal synapses.

TL;DR: Constutive expression of the protein tyrosine kinase Brk in a large proportion of cutaneous T-cell lymphomas and other transformed T- and B-cell populations indicates that Brk may play a key role in lymphomagenesis, hence identifying the kinase as a potential therapeutic target in lymphomas.

TL;DR: Through the functional targeting of an oncogene in primary human tumour cells, it is demonstrated that Bcr‐Abl enhances CML progenitor cell amplification, and that RNAi may be suitable for development as a specific anti‐leukaemia treatment.